Potassium Citrate
| Evidence Level: L5 | Predicted Indications: 8 |
Table of Contents
Potassium Citrate: Familial visceral myopathy
One-Sentence Summary
Potassium citrate is an oral potassium and alkalinising agent. The TxGNN model predicts it may be relevant to familial visceral myopathy, but there are no clinical trials and no publications supporting this prediction, so it rests on computational prediction alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Familial visceral myopathy |
| TxGNN Prediction Score | 0.9995 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Potassium citrate supplies potassium and is metabolised to bicarbonate, which makes it useful as an alkalinising agent and potassium replacement.
Familial visceral myopathy is a genetic disorder of gut smooth muscle motility. Potassium citrate has no established action on its pathophysiology, and no clear mechanistic link has been identified. The high TxGNN score is a computational output only and should not be read as clinical support.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 416X | Not available | Not available | Not recorded |
At least one licence is valid in the local data (1 licence in total, 1 valid, 0 cancelled).
Safety Considerations
Contraindication-type relations (not label text): Relations recorded for this drug include hypertension, kidney disease, impaired renal function, anuria, adrenal insufficiency (including Addison disease), peptic ulcer disease, pancreatitis, hypercalcaemia, nephrocalcinosis, coronary artery disease, myocardial infarction, rhabdomyolysis, metabolic acidosis, diarrhoeal disease and benign prostatic hyperplasia. These are not drawn from the approved label and should be checked against the TGA-approved Product Information (PI).
Drug Interactions: 100 interactions were found in total. Examples of those rated Major:
- Antimuscarinic or anticholinergic agents: atropine, hyoscyamine, homatropine, methscopolamine
- Antihistamines: chlorpheniramine, acrivastine, phenyltoloxamine
- Potassium-raising agents: amiloride
- ACE inhibitors and angiotensin receptor blockers: benazepril, olmesartan, valsartan
- Tricyclic antidepressant: amitriptyline
Moderate examples include ibuprofen, ketorolac, aspirin, aliskiren, doxycycline, pseudoephedrine, amphetamine and dextroamphetamine. Combined use with potassium-raising drugs warrants particular attention because of the risk of hyperkalaemia.
For further safety information, refer to the TGA-approved Product Information (PI).
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no supporting trials or publications and no plausible mechanistic link to the pathophysiology of familial visceral myopathy. It sits at evidence level L5.
To proceed, the following is needed:
- A plausible mechanistic rationale linking potassium citrate to visceral smooth muscle dysfunction
- Preclinical or clinical studies that directly address familial visceral myopathy
- Mechanism of action data and product-specific safety information from the TGA-approved PI
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.